BioMarin EVP earns performance-based RSU awards

Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Guyer Charles Greg reported acquisition or exercise transactions in this Form 4 filing.

BioMarin Pharmaceutical executive Charles Greg Guyer, EVP and Chief Technical Officer, reported three equity awards credited on February 25, 2026. The awards represent performance-based restricted stock units earned for results over 2023–2025 tied to relative total shareholder return, development goals, and core operating margin, vesting on March 15, 2026 if he remains in service.

Insider Trade Summary

Grant/Award: 15,222 shares

Grant/Award 3 txns

Insider Guyer Charles Greg

Role EVP, Chief Technical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,176	$0.00	$0.00
Grant/Award	Common Stock	6,675	$0.00	$0.00
Grant/Award	Common Stock	2,371	$0.00	$0.00

Holdings After Transaction: Common Stock — 96,439 shares (Direct)

Footnotes (5)

F1. Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2. Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F3. Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
F4. Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
F5. Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioMarin (BMRN) executive Charles Greg Guyer report on this Form 4?

Charles Greg Guyer reported three equity awards of common stock on February 25, 2026. These reflect performance-based restricted stock units earned for 2023–2025 under BioMarin’s 2017 Equity Incentive Plan, credited at a zero exercise price as part of his executive compensation.

What performance period do Charles Greg Guyer’s RSU awards at BioMarin (BMRN) cover?

The RSU awards cover performance from 2023 through 2025. They were earned pursuant to performance-based RSU grants under BioMarin’s 2017 Equity Incentive Plan, with formulas tied to relative total shareholder return, development goals, and core operating margin across those three years.

When do the performance-based RSUs reported by BioMarin (BMRN) EVP Charles Greg Guyer vest?

Although already earned, the RSUs vest on March 15, 2026. Vesting is conditioned on Charles Greg Guyer’s continued service through that date, with the potential for earlier vesting only upon certain specified events described in the award terms.

What metrics determine the RSUs earned by BioMarin (BMRN) executive Charles Greg Guyer?

The earned RSUs are based on three metrics over 2023–2025: relative total shareholder return, achievement of specified development goals, and core operating margin over three one-year periods. Each metric corresponds to separate performance-based RSU awards under the 2017 Equity Incentive Plan.

How are Charles Greg Guyer’s RSUs at BioMarin (BMRN) converted into common stock?

Each restricted stock unit is convertible into one share of BioMarin common stock. The Form 4 notes a 1:1 conversion ratio, meaning every vested RSU results in the issuance of a single share upon settlement under the plan’s terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/26/2026 - 08:49 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer Charles Greg

(Last)

(First)

(Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL

94901

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/25/2026⁽¹⁾		A		6,176⁽²⁾⁽³⁾	A	$0	87,393	D
Common Stock	02/25/2026⁽¹⁾		A		6,675⁽³⁾⁽⁴⁾	A	$0	94,068	D
Common Stock	02/25/2026⁽¹⁾		A		2,371⁽³⁾⁽⁵⁾	A	$0	96,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.

2. Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

3. Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.

4. Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

5. Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR